Drug Trial Radar · NCT06564389
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
119
Planned (sponsor's estimate)
Start
Nov 5, 2024
Primary completion
Jun 2, 2027
Study completion Jun 2, 2027
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms
Conditions
- Healthy Participants
- Atopic Dermatitis
Interventions
PF-07832837Drug
escalated doses of PF-07832837
PlaceboOther
placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs) and serious adverse events (SAEs) Following single ascending doses (SAD)Time frame: Baseline up to Day 35
- Number of Participants with Clinically significant Laboratory Abnormalities Following SADTime frame: Baseline up to Day 35
- Number of Participants with Change from Baseline in Electrocardiogram (ECG) Findings Following SADTime frame: Baseline up to Day 35
- Number of Participants with Clinically Significant Change from Baseline in Vital Signs Following SADTime frame: Baseline up to Day 35
- Number of Participants with Clinically Significant Change from Baseline in Cardiac Telemetry Findings Following SADTime frame: Day 1
- Number of Participants With Treatment Emergent Treatment-Related AEs and SAEs Following multiple ascending doses (MAD)Time frame: Baseline up to Day 50
- Number of Participants with Clinically significant Laboratory Abnormalities Following MADTime frame: Baseline up to Day 50
- Number of Participants with Change from Baseline in Electrocardiogram (ECG) Findings Following MADTime frame: Baseline up to Day 50
- Number of Participants With Treatment Emergent Treatment-Related AEs and SAEs in participants with atopic dermatitis (AD)Time frame: Baseline up to Day 80
- Number of Participants with Clinically significant Laboratory Abnormalities in participants with ADTime frame: Baseline up to Day 80
- Number of Participants with Clinically Significant Change from Baseline in Vital Signs in participants with ADTime frame: Baseline up to Day 78
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
Anaheim Clinical Trials, LLC
Anaheim, California · Recruiting
TCR Medical Corporation
San Diego, California · Recruiting
Miami Dermatology and Laser Research
Miami, Florida · Recruiting
Revival Research Institute, LLC
Troy, Michigan · Recruiting
Paddington Testing Company
Philadelphia, Pennsylvania · Recruiting
Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak
Lodz, Łódź Voivodeship, Poland · Not yet recruiting
Centrum Medyczne Angelius Provita
Katowice, Silesian Voivodeship, Poland · Not yet recruiting
Laser Clinic S.C. dr Tomasz Kochanowski dr Andrzej Królicki
Szczecin, West Pomeranian Voivodeship, Poland · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.